Antisense Pharma (Germany) a clinical-stage biopharmaceutical company focused on antisense gene silencing for pancreatic cancer, malignant melanoma and colorectal cancer, closed a $11M Series F financing. Participants include MIG Fonds and Global Asset Fund.
Thanx for your patience as we catch-up.
